CEREBROSPINAL-FLUID DRUG LEVELS OF LEUKEMIC CHILDREN RECEIVING INTRAVENOUS 5 G/M(2) METHOTREXATE

被引：27

作者：

MILLOT, F

RUBIE, H

MAZINGUE, F

MECHINAUD, F

THYSS, A

机构：

[1] EORTC Children's Leukemia Cooperative Group (CLCG) Service d'Hématologie Clinique. CHU, Poitiers

[2] Unité d'Oncologie Pédiatrique, CHU, Toulouse

[3] Unité d'Oncologie Pédiatrique, CHU, Lille

[4] Unité d'Oncologie Pédiatrique, CHU, Nantes

[5] Service d'Oncologie Médicale, Centre Lacassagne, Nice

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 14卷 / 1-2期

关键词：

METHOTREXATE; CEREBROSPINAL FLUID; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHILD;

D O I：

10.3109/10428199409049660

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A multicenter prospective study was conducted in 114 children with acute lymphoblastic leukemia receiving 4 intravenous methotrexate (MTX) courses (5 g/m(2) as a 24 hour-infusion) to determine the diffusion of MTX in cerebrospinal fluid (CSF) and to correlate the drug levels to central nervous system (CNS) relapse occurrence. Serum and CSF levels were measured at the end of 446 MTX courses. A significant correlation was found between CSF and serum MTX concentration. CSF MTX level was greater than 1 mu mol/l in 66% of the courses. Twelve patients (11%) failed to achieve this potentially cytotoxic drug level at the end of the 4 consecutive MTX courses: only one CNS relapse was observed and the mean age of these children was lower than that of the others. To date 9 (7.8%) children had CNS relapse and no difference was observed in terms of CSF MTX levels when compared to data of children free of CNS relapse. With a median follow up of 32 months, pharmacokinetic data during high-dose MTX therapy do not seem to be an exclusive predictive factor of CNS relapse.

引用

页码：141 / 144

页数：4

共 15 条

[1]

Poplack D., Reaman G., Belyer A., Central nervous system preventive therapy with high-dose methotrexate in acute lymphoblastic leukemia, ASCO Proc, 3, (1984)

[2]

Abromowitch M., Ochs J., Pui C.H., Fairclough D., Murphy S.B., Rivera G.K., Efficacy of high-dose methotrexate in childhood acute lymphoblastic leukemia: analysis by contemporary risk classifications, Blood, 71, pp. 866-869, (1988)

[3]

Hryniuk W.N., Bertino J.R., Treatment of leukemia with large doses of methotrexate and folinic acid: clinical biochemical correlates, J. Clin. Invest., 48, pp. 2140-2155, (1969)

[4]

Ettinger L.J., Chervinsky D.S., Freeman A.I., Creaven P.J., Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin lymphoma, Cancer, 50, pp. 1676-1682, (1982)

[5]

Evans W.E., Hutson P.R., Stewart C.F., Methotrexate cerebrospinal lluid and serum concentrations after intermediate-dose methotrexate infusion, Clin. Pharmacol. Ther., 3, pp. 301-307, (1983)

[6]

Maurus R., Boilletot A., Otten J., Treatment of acute lymphoblastic leukemia in children with the BFM protocol

[7]

a cooperative study and analysis of prognostic factors, Haematol. Blood Transf., 30, pp. 466-470, (1987)

[8]

Borsi J.D., Sagen E., Romslo I., 7-hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia, Cancer Chem. Pharmacol., 27, pp. 164-172, (1990)

[9]

Thyss A., Milano G., Deville A., Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies, Eur. J. Cancer Clin. Oncol., 23, pp. 843-847, (1987)

[10]

Borsi J.D., Moe P.J., A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia, Cancer, 60, pp. 5-13, (1987)

← 1 2 →